Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Pediatr Blood Cancer. 2011 Nov 21;58(4):633–635. doi: 10.1002/pbc.23371

Figure 1. Mean absolute neutrophil and monocyte counts and treatment-related toxicities in patients with DS-ALL and NDS-ALL during early therapy.

Figure 1

A. Mean absolute neutrophil counts (ANC) in patients with DS-ALL (black) and NDS-ALL (gray). B. Mean absolute monocyte counts (AMC) in patients with DS-ALL (black) and NDS-ALL (gray). Asterisks indicate time-points at which ANC and AMC significantly differed between groups (p < 0.05). C. The number of toxicities per 1000 follow-up days is shown for patients with DS-ALL (black) versus NDS-ALL (gray). Overall toxicities are shown, as well as the specific categories of microbiologically documented infections, cellulitis, and mucositis. Asterisks indicate significant differences between groups (p < 0.01). DS, Down syndrome; ALL, acute lymphoblastic leukemia; NDS, non-Down syndrome.